Trends in prevalence of comorbidities in heart failure clinical trials
- 15 April 2020
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 22 (6), 1032-1042
- https://doi.org/10.1002/ejhf.1818
Abstract
Aims The primary objective of this systematic review was to estimate the prevalence and temporal changes in chronic comorbid conditions reported in heart failure (HF) clinical trials. Methods and results We searched MEDLINE for HF trials enrolling more than 400 patients published between 2001 and 2016.Trials were divided into HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or trials enrolling regardless of ejection fraction. The prevalence of baseline chronic comorbid conditions was categorized according to the algorithm proposed by the Chronic Conditions Data Warehouse, which is used to analyse Medicare data. To test for a trend in the prevalence of comorbid conditions, linear regression models were used to evaluate temporal trends in prevalence of comorbidities. Overall, 118 clinical trials enrolling a cumulative total of 215 508 patients were included. Across all comorbidities examined, data were reported in a mean of 35% of trials, without significant improvement during the study period. Reporting of comorbidities was more common in HFrEF trials (51%) compared with HFpEF trials (27%). Among trials reporting data, hypertension (63%), ischaemic heart disease (44%), hyperlipidaemia (48%), diabetes (33%), chronic kidney disease (25%) and atrial fibrillation (25%) were the major comorbidities. The prevalence of comorbidities including hypertension, atrial fibrillation and chronic kidney disease increased over time while the prevalence of smoking decreased in HFrEF trials. Conclusion Many HF trials do not report baseline comorbidities. A more rigorous, systematic, and standardized framework needs to be adopted for future clinical trials to ensure adequate comorbidity reporting and improve recruitment of multi‐morbid HF patients.Keywords
This publication has 40 references indexed in Scilit:
- Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection FractionJournal of the American College of Cardiology, 2012
- Trends in Comorbidity, Disability, and Polypharmacy in Heart FailureThe American Journal of Medicine, 2011
- Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology PracticesCirculation, 2010
- Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical JournalsJAMA, 2007
- Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection FractionThe New England Journal of Medicine, 2006
- Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical TrialsJournal of Clinical Oncology, 2005
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)American Heart Journal, 2005
- Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosisJournal of the American College of Cardiology, 2004
- Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?Journal of Clinical Oncology, 2003
- Long-Term Trends in the Incidence of and Survival with Heart FailureThe New England Journal of Medicine, 2002